1 / 11

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Phase 3. HIV Coinfection. Treatment Naïve & Experienced. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5. Wyles D, et al. Clin Infect Dis. 2017 March 29. [ Epub ahead of print]. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5: Study Features.

linus
Download Presentation

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 HIV Coinfection TreatmentNaïve & Experienced Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5 WylesD, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  2. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Study Features Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  3. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Study Design 0 12 24 Week HIV-HCV Coinfected Treatment-naïve & experienced GT 1, 2, 3, 4, or 6 Sofosbuvir-Velpatasvir n =106 SVR12 Drug Dosing: Sofosbuvir-velpatasvir (400/100 mg): fixed-dose combination; one pill once daily Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  4. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Participants Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  5. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Participants Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  6. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Results ASTRAL-5: SVR12 Results by Genotype 101/106 63/66 11/12 11/11 11/12 5/5 Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  7. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Results ASTRAL-5: SVR12 Results by Genotype 2 Relapses 1 LTFU 1 LTFU 1 Withdrew Consent 63/66 11/12 11/12 101/106 11/11 5/5 Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  8. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Results ASTRAL-5: SVR12 Results by Cirrhosis & Treatment Experience 101/106 71/75 30/31 82/87 19/19 210/218 139/144 42/44 27/28 Treatment Experience Cirrhosis Status Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  9. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Resistance Baseline NS5A Resistance-Associated Variants and SVR12 Total, n = 103 100 98% SVR12 100% SVR12 90 80 70 88% No NS5A RAVs 90/103 13% NS5A RAVs 13/103 60 SVR12 (%) 50 40 30 20 10 13/13 88/90 83/86 58/65 24/25 104/104 Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print] 9

  10. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Adverse Events Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

  11. Sofosbuvir-Velpatasvir in HIV-HCV Coinfected PatientsASTRAL-5: Conclusions Source: Wyles D, et al. Clin Infect Dis. 2017 March 29. [Epub ahead of print]

More Related